Granulocyte–colony stimulating factor plus plerixafor inpatients with –thalassemia major results in the effective mobilization of primitiveCD34+ cells with specific gene expression profile

Risultato della ricerca: Articlepeer review

Abstract

Successful gene therapy for β-thalassemia requires optimal numbers of autologous gene-transduced hematopoietic stem and progenitor cells (HSPCs) with high repopulating capacity. Previous studies suggested superior mobilization in these patients by the combination of granulocyte–colony stimulating factor (G-CSF) plus plerixafor over single agents. We mobilized four adult patients using G-CSF+plerixafor to assess the intra-individual variation of the circulating CD34+ cells number and subtypes preand post-plerixafor administration. The procedure was well-tolerated and the target cell dose of ≥8.106 CD34+ cells/kg was achieved in three of them with one apheresis procedure. The addition of plerixafor unanimously increased the number of circulating CD34+ cells, and the frequency of the most primitive CD34+ subtypes: CD34+/38- and CD34+/133+/38- as well as the in vitro clonogenic potency. Microarray analyses of CD34+ cells purified from the leukapheresis of one patient mobilized twice, with G-CSF and with G-CSF+plerixafor, highlighted in G-CSF+plerixafor-mobilized CD34+ cells, higher levels of expression genes involved in HSPC motility, homing, and cell cycles. In conclusion, G-CSF+plerixafor in β-thalassemia patients mobilizes optimal numbers of HSPCs with characteristics that suggest high capacity of engraftment after transplantation.
Lingua originaleEnglish
pagine (da-a)11-17
Numero di pagine7
RivistaThalassemia Reports
Volume7
Stato di pubblicazionePublished - 2017

Fingerprint Entra nei temi di ricerca di 'Granulocyte–colony stimulating factor plus plerixafor inpatients with –thalassemia major results in the effective mobilization of primitiveCD34+ cells with specific gene expression profile'. Insieme formano una fingerprint unica.

Cita questo